Novo Nordisk A/S $NVO Shares Acquired by RPG Investment Advisory LLC

RPG Investment Advisory LLC increased its holdings in Novo Nordisk A/S (NYSE:NVO) by 50.3% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 229,265 shares of the company’s stock after buying an additional 76,691 shares during the quarter. RPG Investment Advisory LLC’s holdings in Novo Nordisk A/S were worth $11,665,000 at the end of the most recent reporting period.

Several other large investors have also recently added to or reduced their stakes in the business. True Wealth Design LLC raised its stake in Novo Nordisk A/S by 209.8% during the 3rd quarter. True Wealth Design LLC now owns 443 shares of the company’s stock valued at $25,000 after acquiring an additional 300 shares in the last quarter. Guerra Advisors Inc bought a new position in shares of Novo Nordisk A/S in the third quarter worth $25,000. American National Bank & Trust acquired a new position in shares of Novo Nordisk A/S during the fourth quarter valued at $28,000. Strengthening Families & Communities LLC bought a new stake in shares of Novo Nordisk A/S during the third quarter valued at about $30,000. Finally, Allianz SE raised its stake in shares of Novo Nordisk A/S by 70.0% during the third quarter. Allianz SE now owns 578 shares of the company’s stock valued at $32,000 after purchasing an additional 238 shares in the last quarter. 11.54% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of equities analysts recently issued reports on the stock. Jefferies Financial Group upgraded shares of Novo Nordisk A/S from an “underperform” rating to a “hold” rating in a research report on Thursday, February 12th. CICC Research started coverage on shares of Novo Nordisk A/S in a research report on Friday, January 9th. They set an “outperform” rating and a $73.50 price target on the stock. Kepler Capital Markets cut shares of Novo Nordisk A/S from a “buy” rating to a “hold” rating in a report on Tuesday, February 24th. TD Cowen lowered shares of Novo Nordisk A/S from a “buy” rating to a “hold” rating and set a $42.00 price objective on the stock. in a research note on Tuesday, March 10th. Finally, Citigroup assumed coverage on Novo Nordisk A/S in a report on Tuesday, January 27th. They set a “neutral” rating on the stock. Four analysts have rated the stock with a Buy rating, nineteen have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Novo Nordisk A/S presently has a consensus rating of “Hold” and an average price target of $65.56.

Novo Nordisk A/S Trading Down 0.2%

Shares of NVO stock opened at $36.92 on Friday. The stock has a 50-day simple moving average of $43.43 and a 200 day simple moving average of $49.79. The stock has a market capitalization of $164.86 billion, a P/E ratio of 10.64, a P/E/G ratio of 8.75 and a beta of 0.73. Novo Nordisk A/S has a fifty-two week low of $35.12 and a fifty-two week high of $81.44. The company has a quick ratio of 0.57, a current ratio of 0.80 and a debt-to-equity ratio of 0.61.

Novo Nordisk A/S (NYSE:NVO) last issued its quarterly earnings results on Tuesday, February 3rd. The company reported $1.01 EPS for the quarter, topping the consensus estimate of $0.90 by $0.11. Novo Nordisk A/S had a net margin of 33.03% and a return on equity of 68.91%. The firm had revenue of $12.43 billion for the quarter, compared to analysts’ expectations of $11.97 billion. On average, sell-side analysts expect that Novo Nordisk A/S will post 3.84 earnings per share for the current fiscal year.

Novo Nordisk A/S Announces Dividend

The firm also recently announced a dividend, which will be paid on Wednesday, April 8th. Investors of record on Monday, March 30th will be issued a $1.2751 dividend. This represents a dividend yield of 723.0%. The ex-dividend date is Monday, March 30th. Novo Nordisk A/S’s payout ratio is presently 50.14%.

Key Headlines Impacting Novo Nordisk A/S

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Novo launched a multi‑month subscription program for Wegovy to lower out‑of‑pocket cost and improve adherence, which could bolster retail uptake and stabilize revenue from self‑pay patients. Slash Your Wegovy Costs: Novo Nordisk Reveals First-Ever Subscription Plan
• Positive Sentiment: Company cites cross‑trial data (ORION) showing oral Wegovy produced greater mean weight loss and fewer discontinuations vs. Lilly’s new pill — a claim that, if borne out commercially, helps defend market share in the oral GLP‑1 segment. Novo Nordisk says Wegovy pill outperforms Lilly’s oral GLP-1 in cross-trial comparison
• Positive Sentiment: Wegovy was cleared by a UK drug‑pricing body for heart‑disease prevention, expanding the eligible patient pool by ~1.2M people — a potential medium‑term sales tailwind in the U.K. Novo’s Wegovy cleared by UK drug price watchdog for heart disease, expanding access by 1.2 million people
• Positive Sentiment: Pipeline progress — including once‑a‑week insulin work and early triple‑agonist studies — supports longer‑term growth optionality beyond current GLP‑1 competition. What Does Novo Nordisk’s (NVO) Once A Week Insulin Mean For Investors?
• Neutral Sentiment: BMO Capital reiterated a Market Perform (hold) rating with a $45 price target — a sign analysts see recovery potential but not an immediate buy catalyst. BMO Capital Maintains a Hold Rating on Novo Nordisk (NVO)
• Neutral Sentiment: Market commentary notes shares have at times held up despite new competition, suggesting investors believe some threats are already priced in. Novo Nordisk shares resilient as FDA approves Eli Lilly GLP-1 weight-loss pill to intensify competition
• Negative Sentiment: Eli Lilly’s oral GLP‑1 (Foundayo) gained FDA approval and is launching, creating a fierce new competitor in the oral obesity market and pressuring expectations for Novo’s market share and pricing. Wall Street sees multi-billion dollar debut for Lilly’s obesity pill despite Novo lead
• Negative Sentiment: Low‑cost generic semaglutide in India forced Novo to cut Wegovy/Ozempic prices by as much as 48% in that market, highlighting pricing vulnerability where generics emerge. Novo Nordisk Shares Down 43% in a Year as Generic Rivals Force 48% Price Cuts
• Negative Sentiment: Policy risk: U.S. proposals to impose heavy tariffs on branded drugs could raise costs or complicate pricing strategies for multinational drugmakers. Trump administration prepares up to 100% pharmaceutical tariffs on some imported drugs
• Negative Sentiment: Valuation and sentiment questions after a ~43% Y/Y drop: investors are re‑pricing Novo on the view that competitive erosion, price competition and upcoming patent expiries will constrain near‑term growth. Is Novo Nordisk (NYSE:NVO) Pricing Fair After A 43% One Year Share Price Decline?

About Novo Nordisk A/S

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.